Breaking Trump Administration Buys Back Offshore Wind Leases for $1.2 Billion Veronica Burton Emerges as Key Player for Second-Year Golden State Valkyries Jalapeño Peppers Linked to Multistate Salmonella Outbreak Traced to Mexican Grower and Distributor Houthi Attacks Breach Yemen Truce, Resulting in Dozens of Casualties Horse Racing’s Triple Crown Faces Major Shifts Amidst Date Change and New Championship Series

Thursday August 6, 2026

Reporter

Nurix Therapeutics, Inc.

3Articles Published

4Communities Covered

Published Articles

Press Release

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Aug 4

Press Release

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Aug 3

Press Release

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Jul 21